Last reviewed · How we verify
NCT05832827: Artemis
First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)
Phase 2 trial testing MK-3475 in Untreated Advanced or Recurrent Thymic Carcinomas in 35 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | National Cancer Center, Japan |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 35 |
| Start date | 4 September 2023 |
| Primary completion | 31 December 2025 |
| Estimated completion | 30 June 2028 |
| Sites | 1 location across Japan |
Drugs / interventions tested
- MK-3475 — full drug profile →
- Lenvatinib (LENVATINIB) — full drug profile →
- Carboplatin (Carboplatin) — full drug profile →
- Paclitaxel — full drug profile →
Conditions studied
- Untreated Advanced or Recurrent Thymic Carcinomas — all drugs for Untreated Advanced or Recurrent Thymic Carcinomas →
Sponsor
National Cancer Center, Japan
Who can join
18 and older, any sex, with Untreated Advanced or Recurrent Thymic Carcinomas. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A phase II, investigator-initiated, non-randomized, open-label, single-arm, multicenter study to evaluate the efficacy and safety of Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab combination for previously untreated advanced or recurrent thymic carcinomas
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Immunotherapy for Thymomas and Thymic Carcinomas: Current Status and Future Directions.
Rajan A, Sivapiromrat AK, McAdams MJ. · · 2024 · cited 12× · PMID 38611047 · DOI 10.3390/cancers16071369 -
Thymic Epithelial Tumor and Immune System: The Role of Immunotherapy.
Perrino M, Cordua N, De Vincenzo F, Borea F, et al · · 2023 · cited 7× · PMID 38067278 · DOI 10.3390/cancers15235574 -
Artemis: A Multicenter, Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of First-Line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas.
Okuma Y, Nomura S, Sakakibara-Konishi J, Tsukita Y, et al · · 2024 · cited 6× · PMID 38413246 · DOI 10.1016/j.cllc.2024.02.002 -
Immunotherapy and Targeted Therapies Efficacy in Thymic Epithelial Tumors: A Systematic Review.
Agrafiotis AC, Brandão M, Berghmans T, Durieux V, et al · · 2023 · cited 6× · PMID 37893096 · DOI 10.3390/biomedicines11102722 -
A Re-Examination of Neoadjuvant Therapy for Thymic Tumors: A Long and Winding Road.
Yu F, Gu Z, Zhang X, Xu N, et al · · 2024 · cited 4× · PMID 38730630 · DOI 10.3390/cancers16091680 -
Narrative review of indication and management of induction therapy for thymic epithelial tumors.
Ajimizu H, Sakamori Y. · · 2024 · cited 3× · PMID 39161586 · DOI 10.21037/med-23-30 -
Thymic epithelial tumors at the crossroads of immunity, autoimmunity, and immunotherapy.
Canaslan K, Moeini Nia F, Baez M, Abolhassani H, et al · · 2026 · PMID 41843177 · DOI 10.1007/s00262-026-04311-4 -
Immune Checkpoint Therapy for Thymic Carcinoma.
Li J, Mao F, Liu H, Chen J. · · 2025 · PMID 41154432 · DOI 10.3390/cancers17203377
Verify or expand the search:
- PubMed search for NCT05832827
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of MK-3475
Trials testing the same drug.
- NCT05879653 — Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD) · Phase 2 · recruiting
- NCT04098068 — Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D) · Phase 2 · completed
- NCT03003468 — Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten C · Phase 1, PHASE2 · completed
- NCT02852655 — A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembr · Phase 1 · active not recruiting
- NCT02289209 — Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head an · Phase 2 · completed
Other National Cancer Center, Japan trials
Trials by the same sponsor.
- NCT07347314 — Enfortumab Vedotin in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-based Combi · Phase 2 · recruiting
- NCT06854939 — A Prospective Study Investigating the Relationship Between Minimal Residual Disease Detection, Monitoring Frequency, and · not yet recruiting
- NCT06673628 — Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma Patients · Phase 2 · recruiting
- NCT06159478 — Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume) · Phase 2 · recruiting
- NCT05433753 — Asian Multicenter Prospective Study in HER2 Positive Early Breast Cancer for Detecting MRD by ctDNA;HARMONY Study · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05832827 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Cancer Center, Japan
- Last refreshed: 23 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05832827.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing